Separate terms with OR to return results that match either term.
 
Clear All
10,000 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
NDC-11 (Package) NDC-9 (Product) Generic Name (Descending) Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
70771-1351-01 70771-1351 methylprednisolone methylprednisolone 32.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral May 1, 2018 In Use
70771-1351-04 70771-1351 methylprednisolone methylprednisolone 32.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral May 1, 2018 In Use
70771-1351-05 70771-1351 methylprednisolone methylprednisolone 32.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral May 1, 2018 In Use
70771-1351-08 70771-1351 methylprednisolone methylprednisolone 32.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral May 1, 2018 In Use
50742-0189-01 50742-0189 methylprednisolone METHYLPREDNISOLONE 4.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral Jan. 17, 2019 In Use
50742-0189-21 50742-0189 methylprednisolone METHYLPREDNISOLONE 4.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral Jan. 17, 2019 July 20, 2020 In Use
54868-0173-00 54868-0173 methotrexate Methotrexate 25.0 mg/mL Chemotherapy Antimetabolite Folic Acid Analog Intra-arterial, Intramuscular, Intrathecal, Intravenous March 26, 2003 In Use
73657-0020-01 73657-0020 melphalan flufenamide Pepaxto 20.0 mg/50mL, 20.0 mg/50mL Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous Feb. 26, 2021 Aug. 13, 2022 No Longer Used
00009-0051-01 00009-0051 medroxyprogesterone acetate Provera 10.0 mg/1 Hormonal Therapy Progestin Oral July 20, 2020 In Use
00009-0065-01 00009-0065 medroxyprogesterone acetate Provera 2.5 mg/1 Hormonal Therapy Progestin Oral Sept. 3, 2019 In Use
00009-0287-01 00009-0287 medroxyprogesterone acetate Provera 5.0 mg/1 Hormonal Therapy Progestin Oral Nov. 11, 2018 In Use
74527-0022-02 74527-0022 margetuximab-cmkb MARGENZA 25.0 mg/mL Immunotherapy Monoclonal Antibody HER2 Intravenous Jan. 15, 2021 In Use
74527-0022-03 74527-0022 margetuximab-cmkb MARGENZA 25.0 mg/mL Immunotherapy Monoclonal Antibody HER2 Intravenous Jan. 15, 2021 In Use
79952-0110-01 79952-0110 loncastuximab tesirine ZYNLONTA 10.0 mg/2mL Immunotherapy Drug Antibody Conjugate CD19 Intravenous April 30, 2021 In Use
68152-0112-01 68152-0112 levoleucovorin KHAPZORY 175.0 mg/3.5mL Ancillary Therapy Chemoprotective Antidote Intravenous Jan. 2, 2019 In Use
68152-0114-01 68152-0114 levoleucovorin KHAPZORY 300.0 mg/6mL Ancillary Therapy Antiemetic Antidote Intravenous Jan. 2, 2019 In Use
00078-0916-61 00078-0916 letrozole and ribociclib Kisqali Femara Co-pack Chemotherapy, Hormonal Therapy Cyclin Dependent Kinase Inhibitor CDK 4/6 + Hormonal Oral May 4, 2017 In Use
00078-0923-61 00078-0923 letrozole and ribociclib Kisqali Femara Co-pack Chemotherapy, Hormonal Therapy Cyclin Dependent Kinase Inhibitor CDK 4/6 + Hormonal Oral May 4, 2017 In Use
70518-1869-00 70518-1869 letrozole Letrozole 2.5 mg/1 Hormonal Therapy Aromatase Inhibitor Oral Feb. 13, 2019 Sept. 23, 2019 No Longer Used
68180-0801-36 68180-0801 lapatinib Lapatinib 250.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR/HER2 Oral Sept. 29, 2020 In Use
10631-0002-31 10631-0002 isotretinoin Absorica LD 8.0 mg/1 Hormonal Therapy Immunomodulator Retinoic Acid Derivative Oral Nov. 20, 2019 In Use
10631-0003-31 10631-0003 isotretinoin Absorica LD 16.0 mg/1 Hormonal Therapy Immunomodulator Retinoic Acid Derivative Oral Nov. 20, 2019 In Use
10631-0004-31 10631-0004 isotretinoin Absorica LD 20.0 mg/1 Hormonal Therapy Immunomodulator Retinoic Acid Derivative Oral Nov. 20, 2019 In Use
10631-0005-31 10631-0005 isotretinoin Absorica LD 24.0 mg/1 Hormonal Therapy Immunomodulator Retinoic Acid Derivative Oral Nov. 20, 2019 In Use
10631-0006-31 10631-0006 isotretinoin Absorica LD 28.0 mg/1 Hormonal Therapy Immunomodulator Retinoic Acid Derivative Oral Nov. 20, 2019 In Use
10631-0007-31 10631-0007 isotretinoin Absorica LD 32.0 mg/1 Hormonal Therapy Immunomodulator Retinoic Acid Derivative Oral Nov. 20, 2019 In Use
71258-0015-02 71258-0015 iobenguane I-131 Azedra 15.0 mCi/mL Chemotherapy Radiopharmaceutical I 131 Intravenous July 30, 2018 In Use
71258-0015-22 71258-0015 iobenguane I-131 Azedra 15.0 mCi/mL Chemotherapy Radiopharmaceutical I 131 Intravenous July 30, 2018 In Use
72730-0101-01 72730-0101 infigratinib TRUSELTIQ 125.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor FGFR Oral May 28, 2021 In Use
72730-0202-01 72730-0202 infigratinib TRUSELTIQ 75.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor FGFR Oral May 28, 2021 In Use
72730-0506-01 72730-0506 infigratinib TRUSELTIQ 50.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor FGFR Oral May 28, 2021 In Use
72730-0111-01 72730-0111 infigratinib TRUSELTIQ 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor FGFR Oral May 28, 2021 In Use
68001-0490-05 68001-0490 imatinib mesylate imatinib mesylate 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral March 26, 2021 In Use
67877-0633-90 67877-0633 imatinib mesylate Imatinib mesylate 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Feb. 1, 2019 In Use
67877-0634-30 67877-0634 imatinib mesylate Imatinib mesylate 400.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Feb. 1, 2019 In Use
72485-0202-90 72485-0202 imatinib mesylate Imatinib mesylate 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral March 15, 2019 In Use
72485-0203-30 72485-0203 imatinib mesylate Imatinib mesylate 400.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral March 15, 2019 In Use
64679-0793-01 64679-0793 imatinib mesylate Imatinib Mesylate 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Jan. 17, 2019 In Use
64679-0793-02 64679-0793 imatinib mesylate Imatinib Mesylate 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Jan. 17, 2019 In Use
64679-0793-03 64679-0793 imatinib mesylate Imatinib Mesylate 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Jan. 17, 2019 In Use
64679-0794-01 64679-0794 imatinib mesylate Imatinib Mesylate 400.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Jan. 17, 2019 In Use
64679-0794-02 64679-0794 imatinib mesylate Imatinib Mesylate 400.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Jan. 17, 2019 In Use
64679-0794-03 64679-0794 imatinib mesylate Imatinib Mesylate 400.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Jan. 17, 2019 In Use
00378-2245-77 00378-2245 imatinib Imatinib Mesylate 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Sept. 28, 2017 In Use
00378-2246-93 00378-2246 imatinib Imatinib Mesylate 400.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Sept. 28, 2017 In Use
00338-3991-01 00338-3991 ifosfamide Ifex 1.0 g/20mL Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous Dec. 30, 1988 In Use
00338-3993-01 00338-3993 ifosfamide Ifex 3.0 g/60mL Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous Dec. 30, 1988 In Use
59572-0515-01 59572-0515 idecabtagene vicleucel Abecma 300000000.0 1/1 Immunotherapy CAR-T BCMA Intravenous March 26, 2021 In Use
59572-0515-02 59572-0515 idecabtagene vicleucel Abecma 300000000.0 1/1 Immunotherapy CAR-T BCMA Intravenous March 26, 2021 In Use
59572-0515-03 59572-0515 idecabtagene vicleucel Abecma 300000000.0 1/1 Immunotherapy CAR-T BCMA Intravenous March 26, 2021 In Use
68788-8455-03 68788-8455 hydrocortisone HYDROCORTISONE 5.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral June 5, 2023 In Use
68788-8455-06 68788-8455 hydrocortisone HYDROCORTISONE 5.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral June 5, 2023 In Use
68788-8455-09 68788-8455 hydrocortisone HYDROCORTISONE 5.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral June 5, 2023 In Use
63759-3028-01 63759-3028 gemcitabine GEMCITABINE 200.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Intravenous June 19, 2019 In Use
63759-3029-01 63759-3029 gemcitabine GEMCITABINE 1.0 g/1 Chemotherapy Antimetabolite Pyrimidine Analog Intravenous June 19, 2019 In Use
25021-0239-05 25021-0239 gemcitabine Gemcitabine 38.0 mg/mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous Jan. 15, 2019 Sept. 30, 2020 No Longer Used
25021-0239-26 25021-0239 gemcitabine Gemcitabine 38.0 mg/mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous Jan. 15, 2019 Feb. 28, 2021 No Longer Used
25021-0239-52 25021-0239 gemcitabine Gemcitabine 38.0 mg/mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous Jan. 15, 2019 Aug. 31, 2020 No Longer Used
62756-0008-60 62756-0008 gemcitabine INFUGEM 10.0 mg/mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous Oct. 1, 2018 July 31, 2023 No Longer Used
62756-0073-60 62756-0073 gemcitabine INFUGEM 10.0 mg/mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous Oct. 1, 2018 July 31, 2023 No Longer Used
62756-0102-60 62756-0102 gemcitabine INFUGEM 10.0 mg/mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous Oct. 1, 2018 July 31, 2023 No Longer Used
62756-0219-60 62756-0219 gemcitabine INFUGEM 10.0 mg/mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous Oct. 1, 2018 July 31, 2023 No Longer Used
62756-0321-60 62756-0321 gemcitabine INFUGEM 10.0 mg/mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous Oct. 1, 2018 July 31, 2023 No Longer Used
62756-0438-60 62756-0438 gemcitabine INFUGEM 10.0 mg/mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous Oct. 1, 2018 No Longer Used
62756-0533-60 62756-0533 gemcitabine INFUGEM 10.0 mg/mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous Oct. 1, 2018 July 31, 2023 No Longer Used
62756-0614-60 62756-0614 gemcitabine INFUGEM 10.0 mg/mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous Oct. 1, 2018 July 31, 2023 No Longer Used
62756-0746-60 62756-0746 gemcitabine INFUGEM 10.0 mg/mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous Oct. 1, 2018 July 31, 2023 No Longer Used
62756-0974-60 62756-0974 gemcitabine INFUGEM 10.0 mg/mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous Oct. 1, 2018 July 31, 2023 No Longer Used
50742-0496-26 50742-0496 gemcitabine GEMCITABINE 38.0 mg/mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous July 1, 2023 In Use
50742-0497-53 50742-0497 gemcitabine GEMCITABINE 38.0 mg/mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous July 1, 2023 In Use
70700-0284-98 70700-0284 fulvestrant FULVESTRANT 50.0 mg/mL Hormonal Therapy Estrogen Receptor Antagonist Intramuscular Aug. 19, 2021 In Use
70710-1688-08 70710-1688 fulvestrant FULVESTRANT 50.0 mg/mL Hormonal Therapy Estrogen Receptor Antagonist Intramuscular Dec. 14, 2021 In Use
16714-0070-02 16714-0070 fulvestrant FULVESTRANT 50.0 mg/mL Hormonal Therapy Estrogen Receptor Antagonist Intramuscular Aug. 23, 2021 In Use
25021-0462-74 25021-0462 fulvestrant fulvestrant 50.0 mg/mL Hormonal Therapy Estrogen Receptor Antagonist Intramuscular Aug. 1, 2019 April 30, 2023 In Use
00591-4385-79 00591-4385 fosaprepitant Fosaprepitant 150.0 mg/1 Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Intravenous Sept. 19, 2019 In Use
68001-0517-36 68001-0517 fosaprepitant fosaprepitant 150.0 mg/5mL Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Intravenous Aug. 23, 2021 July 31, 2024 In Use
50742-0482-50 50742-0482 fluorouracil FLUOROURACIL 2.5 g/50mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous Dec. 21, 2019 In Use
50742-0483-99 50742-0483 fluorouracil FLUOROURACIL 5.0 g/100mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous Dec. 21, 2019 In Use
61314-0304-01 61314-0304 filgrastim-sndz Zarxio 300.0 ug/.5mL, 300.0 ug/.5mL Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor Intravenous, Subcutaneous Sept. 3, 2015 Feb. 28, 2021 No Longer Used
61314-0304-10 61314-0304 filgrastim-sndz Zarxio 300.0 ug/.5mL, 300.0 ug/.5mL Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor Intravenous, Subcutaneous Sept. 3, 2015 Feb. 28, 2021 No Longer Used
61314-0312-01 61314-0312 filgrastim-sndz Zarxio 480.0 ug/.8mL, 480.0 ug/.8mL Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor Intravenous, Subcutaneous Sept. 3, 2015 Feb. 28, 2021 No Longer Used
61314-0312-10 61314-0312 filgrastim-sndz Zarxio 480.0 ug/.8mL, 480.0 ug/.8mL Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor Intravenous, Subcutaneous Sept. 3, 2015 Feb. 28, 2021 No Longer Used
00069-0291-01 00069-0291 filgrastim-aafi Nivestym 300.0 ug/.5mL Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor Subcutaneous Sept. 24, 2018 In Use
00069-0291-10 00069-0291 filgrastim-aafi Nivestym 300.0 ug/.5mL Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor Subcutaneous Sept. 24, 2018 In Use
00069-0292-01 00069-0292 filgrastim-aafi Nivestym 480.0 ug/.8mL Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor Subcutaneous Sept. 24, 2018 In Use
00069-0292-10 00069-0292 filgrastim-aafi Nivestym 480.0 ug/.8mL Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor Subcutaneous Sept. 24, 2018 In Use
00069-0293-10 00069-0293 filgrastim-aafi Nivestym 300.0 ug/mL Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor Intravenous, Subcutaneous March 11, 2019 In Use
00069-0294-10 00069-0294 filgrastim-aafi Nivestym 480.0 ug/1.6mL Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor Intravenous, Subcutaneous March 11, 2019 In Use
65597-0406-01 65597-0406 fam-trastuzumab deruxtecan-nxki Enhertu 100.0 mg/5mL Immunotherapy Drug Antibody Conjugate Topoisomerase I Inhibitor Intravenous Dec. 20, 2019 In Use
69097-0316-02 69097-0316 exemestane EXEMESTANE 25.0 mg/1 Hormonal Therapy Aromatase Inhibitor Oral April 27, 2018 In Use
00378-3097-85 00378-3097 everolimus everolimus 5.0 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral Dec. 15, 2022 In Use
00015-3404-20 00015-3404 etoposide phosphate ETOPOPHOS 100.0 mg/1 Chemotherapy Plant Alkaloid Epipodophyllotoxins Intravenous June 1, 2009 April 30, 2021 No Longer Used
69189-0078-01 69189-0078 esterified estrogens Menest 0.625 mg/1 Hormonal Therapy Estrogen Oral Nov. 23, 2015 May 24, 2017 No Longer Used
00378-7131-93 00378-7131 erlotinib hydrochloride Erlotinib Hydrochloride 25.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral May 9, 2019 Nov. 30, 2022 No Longer Used
00378-7132-93 00378-7132 erlotinib hydrochloride Erlotinib Hydrochloride 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral May 9, 2019 Nov. 30, 2022 No Longer Used
00378-7133-93 00378-7133 erlotinib hydrochloride Erlotinib Hydrochloride 150.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral May 9, 2019 Nov. 30, 2022 No Longer Used
00069-1311-04 00069-1311 epoetin alfa-epbx RETACRIT 20000.0 [iU]/mL Ancillary Therapy Erythropoiesis-Stimulating Agent Intravenous, Subcutaneous Dec. 1, 2020 In Use
00069-1311-10 00069-1311 epoetin alfa-epbx RETACRIT 20000.0 [iU]/mL Ancillary Therapy Erythropoiesis-Stimulating Agent Intravenous, Subcutaneous Nov. 9, 2020 In Use
00069-1305-10 00069-1305 epoetin alfa-epbx RETACRIT 2000.0 [iU]/mL Ancillary Therapy Erythropoiesis-Stimulating Agent Intravenous, Subcutaneous June 18, 2018 In Use
00069-1307-10 00069-1307 epoetin alfa-epbx RETACRIT 4000.0 [iU]/mL Ancillary Therapy Erythropoiesis-Stimulating Agent Intravenous, Subcutaneous June 18, 2018 In Use

Found 10,000 results in 6 milliseconds — Export these results